Detection of Bladder Cancer Using Novel DNA Methylation Biomarkers in Urine Sediments

Background: Bladder cancer (BCa) remains a lethal malignancy that can be cured if detected early. DNA hypermethylation is a common epigenetic abnormality in cancer that may serve as a marker of disease activity. Methods: We selected 10 novel candidate genes from the most frequently hypermethylated genes detected by DNA microarray and bisulfite pyrosequencing of bladder cancers and applied them to detect bladder cancer in urine sediments. We analyzed DNA methylation in the candidate genes by quantitative methylation-specific real-time PCR (qMSP) to detect bladder cancer in urine sediments from 128 bladder cancer patients and 110 age-matched control subjects. Results: Based on a multigene predictive model, we discovered 6 methylation markers (MYO3A, CA10, SOX11, NKX6-2, PENK, and DBC1) as most promising for detecting bladder cancer. A panel of 4 genes (MYO3A, CA10, NKX6-2, and DBC1 or SOX11) had 81% sensitivity and 97% specificity, whereas a panel of 5 genes (MYO3A, CA10, NKX6-2, DBC1, and SOX11 or PENK) had 85% sensitivity and 95% specificity for detection of bladder cancer (area under curve = 0.939). By analyzing the data by cancer invasiveness, detection rate was 47 of 58 (81%) in non-muscle invasive tumors (pTa, Tis, and pT1) and 62 of 70 (90%) in muscle invasive tumors (T2, T3, and T4). Conclusions: This biomarker panel analyzed by qMSP may help the early detection of bladder tumors in urine sediments with high accuracy. Impact: The panel of biomarker deserves validation in a large well-controlled prospectively collected sample set. Cancer Epidemiol Biomarkers Prev; 20(7); 1483–91. ©2011 AACR.

[1]  Gangning Liang,et al.  Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients , 2004, Clinical Cancer Research.

[2]  Bernhard Walter,et al.  Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. , 2007, Urology.

[3]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[4]  Peter A. Jones,et al.  DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight , 2008, Nucleic acids research.

[5]  E A Sickles,et al.  Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. , 1995, AJR. American journal of roentgenology.

[6]  S. Belinsky,et al.  Gene-promoter hypermethylation as a biomarker in lung cancer , 2004, Nature Reviews Cancer.

[7]  Yair Lotan,et al.  Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. , 2008, Journal of the National Cancer Institute.

[8]  K. Kerlikowske,et al.  Positive predictive value of screening mammography by age and family history of breast cancer. , 1993, JAMA.

[9]  A. Gazdar,et al.  Filling the void: urinary markers for bladder cancer risk and diagnosis. , 2001, Journal of the National Cancer Institute.

[10]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[11]  D. Goodlett,et al.  Stromal mesenchyme cell genes of the human prostate and bladder , 2005, BMC urology.

[12]  K. Kerlikowske,et al.  Positive predictive value of specific mammographic findings according to reader and patient variables. , 2009, Radiology.

[13]  E. Messing,et al.  Detection of bladder cancer using a point-of-care proteomic assay. , 2005, JAMA.

[14]  Michael Ittmann,et al.  Identification of Novel Tumor Markers in Prostate, Colon and Breast Cancer by Unbiased Methylation Profiling , 2008, PloS one.

[15]  D. Chan,et al.  Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. , 2000, The Journal of urology.

[16]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[17]  M. Knowles,et al.  Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. , 1998 .

[18]  K. To,et al.  Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  K A Baggerly,et al.  Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. , 2003, BioTechniques.

[20]  Yi Guo,et al.  Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. , 2009, Gastroenterology.

[21]  M. Knowles,et al.  Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer , 2001, Oncogene.

[22]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Uzzo,et al.  Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel , 2004, Clinical Cancer Research.

[24]  M. Swellam,et al.  Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. , 2007, European urology.

[25]  Richard M Hoffman,et al.  Prostate-specific antigen testing accuracy in community practice , 2002, BMC family practice.

[26]  Louis R Kavoussi,et al.  Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. , 1993, Urology.

[27]  François Radvanyi,et al.  Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder , 1997, Oncogene.

[28]  Z. Estrov,et al.  Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact , 2010, Epigenetics.

[29]  Li Zhang,et al.  Genome-Wide Profiling of DNA Methylation Reveals a Class of Normally Methylated CpG Island Promoters , 2007, PLoS genetics.

[30]  G. Papanicolaou,et al.  URINE SEDIMENT SMEARS AS A DIAGNOSTIC PROCEDURE IN CANCERS OF THE URINARY TRACT. , 1945, Science.

[31]  Pearlly S Yan,et al.  High-throughput methylation profiling by MCA coupled to CpG island microarray. , 2007, Genome research.

[32]  R. Hruban,et al.  Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. , 2001, Cancer research.

[33]  S. Goodman,et al.  Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. , 2006, Journal of the National Cancer Institute.

[34]  M. Swellam,et al.  Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. , 2007, The Journal of urology.

[35]  Edmund Chiong,et al.  The use of short tandem repeat profiling to characterize human bladder cancer cell lines. , 2009, The Journal of urology.

[36]  J. Califano,et al.  Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer , 2004, Cancer Research.

[37]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[38]  Peter A. Jones,et al.  Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. , 2010, Cancer research.

[39]  Gary L Rosner,et al.  Tumour vasculature: On the verge of collapse , 2005, Nature Reviews Cancer.

[40]  E. Messing,et al.  Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. , 2005, Urology.

[41]  B. Têtu,et al.  The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. , 1998, British journal of urology.

[42]  H Stepp,et al.  Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. , 1996, The Journal of urology.

[43]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[44]  W. El-Rifai,et al.  CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer , 2004, Modern Pathology.

[45]  T. Ratliff.  Urine markers for bladder cancer surveillance: a systematic review. , 2005, The Journal of urology.

[46]  T. Hajdinjak.  UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. , 2008, Urologic oncology.

[47]  Tongyu Zhu,et al.  A Novel Set of DNA Methylation Markers in Urine Sediments for Sensitive/Specific Detection of Bladder Cancer , 2007, Clinical Cancer Research.

[48]  Elin Gustavsson,et al.  SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies , 2010, Molecular Cancer.

[49]  B. Roe,et al.  A novel member of the WD-repeat gene family, WDR11, maps to the 10q26 region and is disrupted by a chromosome translocation in human glioblastoma cells , 2001, Oncogene.

[50]  R. Sylvester,et al.  Factors affecting recurrence and progression in superficial bladder tumours. , 1995, European journal of cancer.

[51]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.

[52]  M. J. Bailey,et al.  Urinary markers in bladder cancer , 2003, BJU international.

[53]  S. Baylin,et al.  Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon , 1994, Nature Genetics.

[54]  M. Swellam,et al.  Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. , 2010, The Journal of urology.

[55]  L M Schuman,et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer. , 2000, The New England journal of medicine.

[56]  P Schneede,et al.  Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. , 2001, Urology.